Monopar Therapeutics Valuation
| MNPR Stock | USD 22.53 1.83 8.84% |
At this time, the firm appears to be overvalued. Monopar Therapeutics secures a last-minute Real Value of $12.46 per share. The latest price of the firm is $22.53. Our model forecasts the value of Monopar Therapeutics from analyzing the firm fundamentals such as Return On Equity of -1.02, current valuation of 111.64 M, and Shares Owned By Insiders of 42.94 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Monopar Therapeutics' valuation include:
Price Book 24.0376 | Enterprise Value 111.6 M | Enterprise Value Ebitda (2.42) |
Overvalued
Today
Please note that Monopar Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Monopar Therapeutics is based on 3 months time horizon. Increasing Monopar Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Monopar stock is determined by what a typical buyer is willing to pay for full or partial control of Monopar Therapeutics. Since Monopar Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Monopar Stock. However, Monopar Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 22.53 | Real 12.46 | Target 8.5 | Hype 20.63 | Naive 23.77 |
The intrinsic value of Monopar Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Monopar Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Monopar Therapeutics helps investors to forecast how Monopar stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Monopar Therapeutics more accurately as focusing exclusively on Monopar Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Monopar Therapeutics' intrinsic value based on its ongoing forecasts of Monopar Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Monopar Therapeutics' closest peers.
Monopar Therapeutics Cash |
|
Monopar Valuation Trend
Monopar Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Monopar Therapeutics' financial worth over time. Using both Monopar Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Monopar Therapeutics Total Value Analysis
Monopar Therapeutics is now projected to have valuation of 111.64 M with market capitalization of 118.91 M, debt of 1.76 M, and cash on hands of 16.46 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Monopar Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
111.64 M | 118.91 M | 1.76 M | 16.46 M |
Monopar Therapeutics Asset Utilization
One of the ways to look at asset utilization of Monopar is to check how much profit was generated for every dollar of assets it reports. Monopar Therapeutics secures a negative usage of assets of -0.53 %, losing $0.005345 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Monopar Therapeutics shows how discouraging it operates for each dollar spent on its assets.Monopar Therapeutics Ownership Allocation
The market capitalization of Monopar Therapeutics is $118.91 Million. Monopar Therapeutics holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Monopar Therapeutics Profitability Analysis
Net Loss for the year was (8.4 M) with profit before overhead, payroll, taxes, and interest of 0.About Monopar Therapeutics Valuation
The stock valuation mechanism determines Monopar Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Monopar Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Monopar Therapeutics. We calculate exposure to Monopar Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Monopar Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 110.2 K | 97.9 K |
Monopar Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Monopar Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 14.5 M |
Monopar Therapeutics Current Valuation Indicators
Monopar Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Monopar Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Monopar Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Monopar Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Monopar Therapeutics' worth.Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.